enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Key figures
- Market capClose on Nov 10, 2026
- $111.9M
- Insider buysLast 90 days, $10.1K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 60
- 13F valueReported value at the end of Q2 2026
- $86.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$117.3M
- No comparable prior period
- Free cash flow, FY2025
- -$100.7M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.62M
- Shares sold short
- Change
- +121.4K
- +8.1% vs. previous
- Days to cover
- 1.92
- At average daily volume
Superinvestors holding ENGN, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ENGN at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by enGene Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:40 PM ET | Sep 22 | 2 days | Grossman WilliamInterim Chief Medical Officer | PPurchase | +5.10K | $1.97 | +$10.1K | New position5.10K after | |
| Nov 1, 2024 (view filing)4:15 PM ET | Oct 30 | 2 days | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +561.8K | $8.90 | +$5.00M | +22.7%3.03M after | |
| Oct 18, 2024 (view filing)4:15 PM ET | Dec 27, 2023-Oct 8, 2024 | 296 daysLate | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +470.6K | $6.40 | +$3.01M | +23.5%2.47M after | 13 lots |
| Oct 1, 2024 (view filing) | Sep 27 | 4 days | Cooper Ronald Harold WilfredChief Executive Officer | PPurchase | +10.0K | $5.70 | +$57.0K | New position10.0K after | |
| Apr 22, 2024 (view filing) | Apr 18-22 | 4 days | Fonds De Solidarite Des Travailleurs Du Quebec10% Owner | SSale | −52.5K | $15.00 | −$788.0K | −1.7%3.04M after | 3 lots |
Top 10 13F holders, Q2 2026
See all 60 holdersThe largest institutional positions in enGene Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FCPM III Services B.V. | 9,632,561 | $16.7M | 2.22% | 00.0% | Unchanged |
| BML Capital Management, LLC | 6,669,908 | $11.5M | 6.59% | +6,669,908 | New |
| Siren, L.L.C. | 6,256,662 | $10.8M | 0.22% | +1,003,503+19.1% | Added |
| Perceptive Advisors LLC | 4,822,169 | $8.34M | 0.13% | −1,005,337−17.3% | Reduced |
| Ameriprise Financial Inc | 2,675,876 | $4.63M | 0.00% | +2,675,876 | New |
| Nextech Invest, Ltd. | 2,324,943 | $4.02M | 0.19% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 2,104,986 | $3.64M | 0.17% | +1,971,300+1,474.6% | Added |
| Vestal Point Capital, LP | 1,667,430 | $2.88M | 0.07% | −497,570−23.0% | Reduced |
| Acorn Capital Advisors, LLC | 1,271,257 | $2.20M | 0.60% | +1,271,257 | New |
| Peapod Lane Capital LLC | 1,102,149 | $1.91M | 1.29% | +1,102,149 | New |
Holders of 5% or more of ENGN
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of enGene Therapeutics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 13G/A | 9.99%6.90M shares | 0.00 ppfrom 9.99% | Nov 18, 20252 filings | Aug 14, 2026 | SEC |
| BML Investment Partners, L.P. | 13G/A | 9.95%6.67M shares | +2.15 ppfrom 7.80% | May 13, 20262 filings | May 14, 2026 | SEC |
| Invus Global Management, LLC | 13G/A | 9.30%6.26M shares | +1.50 ppfrom 7.80% | May 5, 20262 filings | Aug 13, 2026 | SEC |
| Invus Global Management, LLC | 13G | 6.30%4.24M shares | New | Jan 27, 20261 filing | Jan 27, 2026 | SEC |
| Acorn Bioventures, L.P. | 13G | 5.00%3.36M shares | New | Jul 22, 20261 filing | Jul 22, 2026 | SEC |